Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

New study finds chemicals used for water purification can lead to food allergies

Food allergies are on the rise, affecting 15 million Americans. And according to a new study published in the December issue of Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), pesticides and tap water could be partially to blame.

3 Dec 2012

Tdap well tolerated in over-65s

Off-label use of tetanus–diptheria–acellular pertussis vaccine in senior patients results in no more adverse events than the tetanus and diphtheria vaccine, a US study shows.

30 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction.

9 Nov 2012

Only 15% of patients with anaphylaxis receive epinephrine from paramedics

Epinephrine is the first line of treatment for patients suffering from anaphylaxis, a life-threatening allergic reaction.

9 Nov 2012

More than half of allergic children can tolerate baked hen's eggs

Avoiding sweet treats like pumpkin bread and cookies this holiday season might not be necessary for children with egg allergies. New studies presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found 56 percent of allergic children can tolerate baked hen's egg, while 55 percent outgrow their egg allergy entirely.

9 Nov 2012

High family income, hygiene habits can increase risk of peanut allergies in children

Peanut allergies are rising among American children and one reason might be due to economic status. According to a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, greater rates of peanut allergy are found in families with higher economic status. This supports the "hygiene hypothesis" of many allergists.

9 Nov 2012

Women more likely to develop spice allergy

Imagine a world where you could never dine away from home, wear makeup, smell of sweet perfumes or eat a large percentage of food on store shelves. According to allergists at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting that is kicking off today in Anaheim, Calif., that is the world for 2 to 3 percent of individuals living with a spice allergy.

8 Nov 2012

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Santarus, Inc. and Pharming Group NV today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met the primary endpoint of time to beginning of symptom relief.

7 Nov 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Sanofi Pasteur, the vaccines division of Sanofi, presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV).

23 Oct 2012

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone (Influenza Virus Vaccine).

20 Oct 2012

EMA CHMP issues positive opinion to Savient's KRYSTEXXA for treatment of chronic gout

Savient Pharmaceuticals, Inc. and its wholly owned subsidiary, Savient Pharma Ireland Limited, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

19 Oct 2012

Longer looks: Mitt Romney's health care legacy; Closing of Philly hospitals brings 'grim consequences;' Young doctors and their apps

A journey into the places, people, and decisive moments that made the men who are competing for the presidency. ...As governor, Romney knew he needed what political pros called a "legacy issue" if he wanted to run for president one day. He devoted his energy towards reforming health care, an issue that Democrats had been grappling with and a problem that cost the state dearly as taxpayers bore the brunt of covering the uninsured.

11 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012

Severe egg allergy treatment shows promise

Specific oral tolerance induction with raw hen’s egg can reduce the severity of egg allergy in affected children, show study findings.

14 Sep 2012

Anaphylaxis News and Research

Further Reading

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

New study finds chemicals used for water purification can lead to food allergies

Tdap well tolerated in over-65s

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Lone star tick causes alpha-gal meat sensitivity in regional population

Only 15% of patients with anaphylaxis receive epinephrine from paramedics

More than half of allergic children can tolerate baked hen's eggs

High family income, hygiene habits can increase risk of peanut allergies in children

Women more likely to develop spice allergy

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

EMA CHMP issues positive opinion to Savient's KRYSTEXXA for treatment of chronic gout

Longer looks: Mitt Romney's health care legacy; Closing of Philly hospitals brings 'grim consequences;' Young doctors and their apps

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Severe egg allergy treatment shows promise

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News